通过通过IL-7细胞因子治疗恢复CD8T细胞动态,使免疫检查点阻断在T淋巴缺血中的有效性
Yeon-Woo Kang1, Donghoon Choi2, Dain Moon1
1Department of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea.
Frontiers in immunology
|January 7, 2025
概括
型淋巴缺血 (TLP) 会影响抗PD-1 癌症治疗. 再组合IL-7 (rhIL-7-hyFc) 与抗PD-1结合恢复T细胞,增强TLP小鼠的瘤回归和存活率.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症治疗 癌症治疗
背景情况:
- 癌症患者常见的T-淋巴缺血症 (TLP) 降低了免疫检查点阻塞 (ICB) 治疗的有效性.
- 传统的化疗/放射疗法可能会使TLP恶化,进一步阻碍抗瘤免疫力.
研究的目的:
- 调查TLP严重程度对ICB响应能力的影响.
- 探索治疗策略,包括IL-7,以增强TLP的抗瘤免疫力.
主要方法:
- 已建立的TLP小鼠模型 (thymectomy,anti-Thy1) 模仿临床TLP.
- 在具有不同瘤负担的TLP小鼠中评估了抗PD-1疗效.
- 在TLP中使用流细胞计分析了免疫细胞群和机制.
- 在TLP小鼠中评估了抗PD-1和rhIL-7-hyFc治疗的组合.
主要成果:
- 在TLP小鼠中,抗PD-1疗法的疗效显著降低.
- TLP改变了瘤透的淋巴细胞,减少了对瘤反应的CD8T细胞,并影响了克隆扩张.
- rhIL-7-hyFc恢复了全身T细胞,促进了内CD8T细胞的增殖,并增加了类似干细胞的祖先细胞.
- 结合治疗的rhIL-7-hyFc和抗PD-1实现显著的瘤回归和改善的生存率.
结论:
- 通过调节CD8 T细胞格局,IL-7在提升TLP中的ICB疗效方面发挥着至关重要的作用.
- 为优化TLP患者的癌症治疗,建议采用顺序治疗方法 (常规疗法,其次是IL-7和ICB).
关键词:
在T-lymphopenia中,患者可能出现T-lymphopenia.化疗/辐射疗法介质蛋白-7-7的使用方法像干细胞一样的CD8 T细胞已经耗尽.与治疗相关的淋巴缺血症透到瘤中的淋巴细胞对瘤有反应性的CD8T细胞.更多相关视频
09:26In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 15, 2013
14.0K
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.7K
相关概念视频
01:27Tumor Immunotherapy
391
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
391
01:24T Cell Types and Functions
612
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
612